4 results
To determine the safety and efficacy of Dimebon in patients with mild to moderate Huntington Disease
To determine the benefit of Dimebon as compared to placebo on the primary measure of cognition and memory, the Alzheimer*s Disease Assessment Scale * cognitive subscale (ADAS-cog); andTo determine the benefit of Dimebon as compared to placebo on the…
To evaluate the long-term safety and tolerability of Dimebon in AD patients who have successfully completed 26 weeks of blinded treatment in the CONNECTION Study (DIM14) (hereafter referred to as *CONNECTION*).
To investigate the effectiveness of triple therapy (ICS/ long-acting beta 2 agonist (LABA)/long-acting muscarine antagonist (LAMA)) on the change in health status, measured with the Clinical COPD Questionnaire (CCQ), in symptomatic ICS-naive COPD…